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Summary
 Aim To analyze the physical parameters of interstitial HDR brachytherapy and their 
inﬂ uence on the risk of soft tissue ﬁ brosis.
 Materials/Methods A retrospective analysis of 54 breast cancer patients treated between 1994–1999 
in the Brachytherapy Department of the Oncological Centre in Bydgoszcz was 
performed. Minimum follow up period was 41 months and the maximum was 89 
months. The mean follow up period was 65 months. Owing to statiscally signiﬁ cant 
differences between the groups, when compared to a normal distribution, the U 
Mann-Whitney non-parametrical test was used as the method for comparison.
 Results Out of the nine parameters analysed, three were found to be associated with in-
creased risk of ﬁ brosis occurrence. Reference volumes V100, V150 and V200 
showed statistically signiﬁ cant differences (p<0.05).
 Conclusions In breast conserving therapy a number of parameters inﬂ uence the results of 
treatment. Our own studies have shown that among the risk factors responsi-
ble for ﬁ brosis are: reference volume V100 (the volume of tissue surrounded by 
100% isodose), V150 (volume of tissue surrounded by 150% isodose) and V200 
(volume of tissue surrounded by 200% isodose).
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BACKGROUND
Breast cancer is the most commonly occurring 
malignant tumour among women. In the ear-
ly stages, breast conservation therapy (BCT) is 
used. A routine procedure may involve lumpec-
tomy and whole breast radiotherapy with exter-
nal beams and tumour bed boost. Such treat-
ment allows to active of results similar to those 
of amputation.
In order to increase the dose around the tumour 
bed, external beams or interstitial HDR brachy-
therapy are used. This treatment is based on local 
recurrence data showing that the highest recur-
rence risk is in the area of earlier lumpectomy [1–
3]. Experience from studies in selected institutions, 
and from controlled clinical studies, suggests that 
by increasing the dose to the post-tumour area it is 
possible to decrease the risk of recurrence [4,5].
The method used is determined mainly by the 
original localisation of the cancer and the ther-
apeutic options available at the institute.
In multi-disciplinary treatment, a number of pa-
rameters inﬂ uence the cosmetic effects. The 
major factors are: tumour size, volume of the 
removed tissue, total dose, fraction dose of irra-
diation and the dose rate.
AIM
The aim of this study was to analyse physical pa-
rameters of interstitial HDR brachytherapy and 
their inﬂ uence on the risk of soft tissue ﬁ brosis 
in the irradiated breast.
MATERIALS AND METHODS
A retrospective analysis of 54 breast cancer pa-
tients treated in the Brachytherapy Department 
at the Oncological Centre of Bydgoszcz between 
July 1994 and December 1999 was performed. 
The minimum follow up period was 41 months, 
maximum follow up was 89 months, and the mean 
follow up period was 65 months. All patients had 
undergone lumpectomy and axillary clearance. 
In all cases but 6, an invasive ductal carcinoma 
was found. In one case, medullary carcinoma was 
detected. In three cases, lobular invasive carci-
noma was diagnosed. Additionally, two cases of 
DCIS were detected.
In each case, conventional radiotherapy with op-
posing tangential ﬁ elds was applied to the whole 
breast. The total dose was from 50 to 50.4 Gy with 
dose fractions from 1.8 to 2.0 Gy. Up to 14 days 
after radiotherapy, interstitial brachytherapy to 
the area after lumpectomy was applied, in order 
to increase the local dose.
Insertion of the needles was carried out under 
short-term anaesthesia. Hospitalisation lasted 
24 hours.
The needles were introduced using coordinating 
plates, which ensured a constant geometrical pat-
tern. According to the Paris system, the needles 
were placed in parallel positions and thus cre-
ated triangular patterns [6]. The distances be-
tween the needles was ﬁ xed at 16 mm. Double-
plane implants were most frequently used, with 
an average of 6 needles (min 3, max 18).
The dose range of interstitial brachytherapy used 
was from 5 to 20 Gy and was speciﬁ ed accord-
ing to the Paris system [6]. In all cases, the ref-
erence isodose was estimated as 85% of the dose 
value at base points marked in the central plane 
of the implant. Treatment was by isotope Ir-192, 
HDR method (high dose rate), with source ac-
tivity from 10 to 5 Ci.
The area for irradiation was determined on the 
basis of pre-surgical mammography, ultrasound 
examination, clinical examination, the surgeon’s 
report, the pathologist’s report and, in some cas-
es, post-surgical mammography. The boost area 
comprised the maximum tumour dimension 
speciﬁ ed in the pathologist’s report and a mar-
gin from 1 to 3 cm, which depended on the mi-
croscopic margin and histological nature of the 
tumour [7].
The treatment was well tolerated by all patients 
and no early complications were observed.
An observation period followed. The ﬁ rst follow-
up examinations took place after 4 weeks and 
thereafter, every 3–6 months. Annual follow up 
examinations started 5 years after completion 
of therapy. Cosmetic effects were evaluated by 
2 doctors independently. Presence or absence 
of ﬁ brosis, compared to the healthy breast, was 
evaluated.
Statistical analysis was carried out using the pro-
gram STATISTICA 6.0. For all parameters, the 
correlation of patients’ sample data was compared 
with normal distributions using the Kołmogorow-
Smirnow test, with Lileforse’s correction. In most 
Original Paper Rep Pract Oncol Radiother, 2005; 10(3): 119-123
120
cases statistically signiﬁ cant differences were 
found. Therefore, for inter-group comparison 
of independent samples, the U Mann – Whitney 
test was used. In all tests, the probability’s border 
value was estimated at p<0.05.
RESULTS
Physical parameters of interstitial brachytherapy 
were analysed. Patients were divided into groups 
1 and 2. The ﬁ rst group included patients with 
ﬁ brosis detected around the treated breast. The 
second group included patients without ﬁ bro-
sis. The inﬂ uence of the following parameters 
was analysed in both groups: number of needles, 
number of planes, active length, total dose, V100 
(the volume of the tissues surrounded by 100% 
isodose), V150 (the volume of the tissues sur-
rounded by 150% isodose), V200 (the volume 
of the tissues surrounded by 200% isodose), QI 
quality index and UI uniformity index.
In Table 1, medium values and standard deviations 
for the analysed parameters in both groups are 
presented. Statistically signiﬁ cant differences were 
found in case of three parameters. These parame-
ters were reference volumes V100, value (p=0.0236), 
V150 (p=0.0221) and V200 (p=0.0311).
DISCUSSION
Soft tissue ﬁ brosis is a common side effect of radi-
otherapy. The risk of its occurrence may be deter-
mined from the total dose used [8,9]. Bentzen et 
al, described this in the case of patients after mas-
tectomy and irradiated on the sides of the chest 
[10]. The study found that a 50% risk of ﬁ brosis 
occurrence is associated with a dose of 47.5 Gy giv-
en in 22 fractions. On the other hand, the studies 
carried out by Borger et al., showed that in case 
of breast conserving treatment, when radiother-
apy is combined with interstitial brachytherapy, a 
50% risk of ﬁ brosis occurrence is associated with 
a dose of 72 Gy. These signiﬁ cant discrepancies 
are mainly due to application of various surgical 
methods and therefore, as a result, varying blood-
vessel changes within the irradiated ﬁ eld. Blood-
vessel changes are one of the factors known to 
increase the risk of soft tissue ﬁ brosis. Another 
factor, one we know little about, is the difference 
in the radiosensitivities of the skin and the glan-
dular or fatty tissue of the breast. Furthermore, 
this factor may be of high diversity.
Polgar and Moreno [11,12] described the rela-
tionship between irradiation dose and ﬁ brosis 
occurrence in cases of interstitial high dose rate 
brachytherapy. Similar studies of patients with 
limited area irradiation after lumpectomy were 
described by Lawenda et al. [13].
Our own studies showed that reference volumes 
V100, V150 and V200 inﬂ uence the risk of ﬁ bro-
sis occurrence. The V100 parameter is mainly de-
termined by the tumour size and the extent of 
soft tissue removal. The correlation between the 
amount of tissue lost in surgery and the risk of 
ﬁ brosis occurrence has been the subject of nu-
merous studies [15–17]. The V150 and V200 pa-
rameters are its derivatives, but depend mainly 
on implant quality. Using different numbers of 
catheters, planes and by carrying out geometri-
cal optimisation we inﬂ uenced the above-men-
tioned parameters, thereby decreasing the prob-
ability of ﬁ brosis occurrence. Our studies did not 
show, as we had expected, any statistically signif-
icant inﬂ uence from the number of tracks and 
implant planes used. This is an inversely propor-
tional relationship and was described by the au-
thors of studies carried out at the Oncological 
Centre in Warsaw (A. Kulik, personal message) 
and is logically justiﬁ ed.
Another issue is the time of ﬁ brosis occurrence 
and the period of follow up. In this study, to eval-
uate the effects of ﬁ brosis, a minimal period of 
3 years after the end of brachytherapy, was tak-
en into consideration. Apparently, the risk is 
highest within the ﬁ rst 3 years after radiother-
apy, however, following years of follow up also 
show slightly increased risk, a change which dis-
appears entirely in the ninth year of the follow 
up period [14].
The studies carried out, were aimed at analysing 
various physical aspects and their inﬂ uence on the 
risk of ﬁ brosis occurrence. Therefore, a number 
of other clinical treatment factors which may have 
an inﬂ uence on ﬁ brosis occurrence, were not 
taken into consideration. Among these are: the 
range and type of surgery, chemotherapy or pho-
ton energy used in teleradiotherapy.
CONCLUSIONS
To summarise, a number of factors have an in-
ﬂ uence on the ﬁ nal cosmetic effect and on ﬁ bro-
sis risk in breast conserving therapy. One of the 
greatest factors is the quality of brachytherapy 
used. It should be based on multi-plane implants 
with suitable distance between the source and skin 
placement (min. 5 mm) and high dose area re-
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duction (V150 and V200) in the target. Another 
important step would be to determine the target 
on the basis of magnetic resonance or ultrasound 
examination which would make clinical brachy-
therapy’s introduction more possible and its ap-
plication more standard than currently.
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